These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19735356)

  • 41. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
    Fusco F; Sicuteri R; Rossi A; Kontodimas S; Haro JM; Imbimbo C; Mirone V;
    Asian J Androl; 2009 Sep; 11(5):629-37. PubMed ID: 19701217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
    Mirone V; Fusco F; Rossi A; Sicuteri R; Montorsi F
    BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
    Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
    BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Benefits of tadalafil in sexual activity-related time concerns].
    Yuang RQ
    Zhonghua Nan Ke Xue; 2010 Jun; 16(6):572-5. PubMed ID: 20608366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study.
    Cairoli C; Reyes LA; Henneges C; Sorsaburu S
    Int Braz J Urol; 2014; 40(3):390-9. PubMed ID: 25010306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient education series. Erectile dysfunction.
    Lewis JH; Rosen R; Goldstein I
    Nursing; 2005 Feb; 35(2):64. PubMed ID: 15706284
    [No Abstract]   [Full Text] [Related]  

  • 50. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
    BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report.
    Agrawal A; Tutuian R; Hila A; Castell DO
    Dig Dis Sci; 2005 Nov; 50(11):2059-62. PubMed ID: 16240215
    [No Abstract]   [Full Text] [Related]  

  • 52. [Update of PDE5 inhibitors as treatment of ED].
    Lu YN; Chen B
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How new drugs help treat erectile dysfunction.
    Weeks B; Ficorelli CT
    Nursing; 2006 Jan; 36(1):18-9. PubMed ID: 16394991
    [No Abstract]   [Full Text] [Related]  

  • 54. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME; Althof SE; Perelman MA
    Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.
    Mathers MJ; Klotz T; Brandt AS; Roth S; Sommer F
    BJU Int; 2008 May; 101(9):1129-34. PubMed ID: 18190629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphodiesterase type 5 inhibitor abuse: a critical review.
    Lowe G; Costabile R
    Curr Drug Abuse Rev; 2011 Jun; 4(2):87-94. PubMed ID: 21696344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sildenafil or vardenafil nonresponders' erectile response to tadalafil.
    Ozgur BC; Gonenc F; Yazicioglu AH
    Urol J; 2009; 6(4):267-71. PubMed ID: 20027555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
    van Ahlen H; Wahle K; Kupper W; Yassin A; Reblin T; Neureither M
    J Sex Med; 2005 Nov; 2(6):856-64. PubMed ID: 16422810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
    Rosen RC; McKenna KE
    Annu Rev Sex Res; 2002; 13():36-88. PubMed ID: 12836729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.